BI Asset Management Fondsmaeglerselskab A S Buys 26,812 Shares of CME Group Inc. $CME

BI Asset Management Fondsmaeglerselskab A S lifted its position in CME Group Inc. (NASDAQ:CME) by 167.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,781 shares of the financial services provider’s stock after purchasing an additional 26,812 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in CME Group were worth $11,559,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Jessup Wealth Management Inc grew its position in shares of CME Group by 0.5% during the 2nd quarter. Jessup Wealth Management Inc now owns 7,969 shares of the financial services provider’s stock worth $2,197,000 after buying an additional 36 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of CME Group by 0.7% in the second quarter. First Horizon Advisors Inc. now owns 5,269 shares of the financial services provider’s stock valued at $1,453,000 after acquiring an additional 36 shares in the last quarter. MBM Wealth Consultants LLC lifted its stake in CME Group by 2.7% in the second quarter. MBM Wealth Consultants LLC now owns 1,422 shares of the financial services provider’s stock worth $392,000 after acquiring an additional 37 shares during the period. Whittier Trust Co. of Nevada Inc. grew its holdings in CME Group by 0.8% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 5,021 shares of the financial services provider’s stock worth $1,384,000 after acquiring an additional 38 shares in the last quarter. Finally, Atlatl Advisers LLC grew its holdings in CME Group by 1.8% during the 3rd quarter. Atlatl Advisers LLC now owns 2,126 shares of the financial services provider’s stock worth $574,000 after acquiring an additional 38 shares in the last quarter. 87.75% of the stock is currently owned by hedge funds and other institutional investors.

CME Group Stock Performance

Shares of CME stock opened at $297.38 on Friday. CME Group Inc. has a 12-month low of $239.70 and a 12-month high of $302.20. The business’s fifty day simple moving average is $276.48 and its 200-day simple moving average is $272.84. The company has a current ratio of 1.03, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. The company has a market cap of $107.24 billion, a PE ratio of 26.65, a PEG ratio of 3.32 and a beta of 0.27.

CME Group (NASDAQ:CME) last announced its earnings results on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.75 by $0.02. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.64 billion. CME Group had a return on equity of 14.65% and a net margin of 62.45%.The firm’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.52 EPS. Analysts expect that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

Key Headlines Impacting CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Q4 results and record annual figures: CME posted Q4 EPS of $2.77 and revenue of ~$1.65B, with record 2025 annual revenue of $6.5B and all-time-high average daily volume in Q4 — fundamental beat that supports revenue resilience and margin strength. CME Group Q4 Earnings and Revenues Top Estimates, ADV Rises Y/Y
• Positive Sentiment: Management guidance and strategy: Management said fee adjustments could lift revenue ~1%–1.5% and reiterated plans to expand 24/7 crypto and securities clearing — a structural growth lever if adoption ramps. CME targets 1%-1.5% revenue lift; expanding 24/7 crypto
• Positive Sentiment: Morgan Stanley maintains Buy: A Wall Street analyst reiterated a Buy / Overweight view citing CME’s resilient fee-based franchise and underappreciated structural growth, supporting medium‑term upside. Morgan Stanley maintains Buy
• Neutral Sentiment: RBC raises price target modestly to $302 (sector perform): a small lift in analyst valuation but not a clear catalyst given the modest upside. RBC raises PT to $302
• Neutral Sentiment: Raymond James trims price target slightly to $310 but keeps Outperform — minimal change to the investment thesis. Raymond James adjusts PT to $310
• Neutral Sentiment: CEO says firm is exploring a proprietary token and tokenized cash pilots (with Google) to enable faster collateral movement and potential 24/7 trading — strategically important but execution, regulatory and adoption risks leave near-term impact uncertain. CME exploring issuing token
• Negative Sentiment: JPMorgan keeps an Underweight rating and has a $266 target (below current levels), signaling downside risk if volumes or product adoption slow relative to expectations. JPMorgan maintains Underweight, PT $266
• Negative Sentiment: Analyst caution / valuation note: a Seeking Alpha piece argues quality doesn’t automatically justify a buy today — a reminder that valuation and long-term growth execution should be assessed before adding exposure. CME Group: Quality Shines Through, But It Doesn’t Mean To Buy

Insider Activity

In other CME Group news, CEO Terrence A. Duffy sold 25,000 shares of CME Group stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $269.55, for a total transaction of $6,738,750.00. Following the completion of the transaction, the chief executive officer owned 65,804 shares in the company, valued at approximately $17,737,468.20. This trade represents a 27.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William R. Shepard acquired 251 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The stock was bought at an average cost of $278.37 per share, with a total value of $69,870.87. Following the acquisition, the director owned 258,710 shares in the company, valued at approximately $72,017,102.70. This trade represents a 0.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CME has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on shares of CME Group from $262.00 to $266.00 and gave the company an “underweight” rating in a report on Thursday. Piper Sandler lifted their price objective on shares of CME Group from $296.00 to $313.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. UBS Group restated a “neutral” rating on shares of CME Group in a report on Tuesday, January 6th. Argus cut their price target on CME Group from $308.00 to $295.00 in a report on Friday, October 31st. Finally, Keefe, Bruyette & Woods boosted their price target on CME Group from $283.00 to $287.00 and gave the stock a “market perform” rating in a research report on Monday, October 13th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $295.82.

CME Group Company Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.